News & Trends - Biotechnology
Aussie biopharma sets sights on 2nd-gen COVID vaccine
An Australian biopharma company is developing the world’s first COVID-19 vaccine which can offer immunity against all variants.
EnGeneIC is currently conducting anti-COVID-19 vaccine trials with its patented platform technology based around a biological nanocell (EDV; EnGeneIC Dream Vector) in Sydney and Melbourne.
Clinical trials have shown the novel vaccine stimulates a completely different immune pathway from other vaccines, producing “high affinity” antibodies that neutralise all COVID-19 variants.
Initially developed as a breakthrough in cancer treatment, these EDVs are loaded with anti-viral molecules to deliver a world-first nano-cellular COVID-19 vaccine.
Based on the company’s trials treating late-stage cancer patients, EnGeneIC believes its COVID-19 EDV vaccine will also be effective in those who are immune-compromised.
Pharma and medtech companies voice commitment to NAIDOC Week
EnGeneIC founders and joint CEOs, Dr Himanshu Brahmbhatt and Dr Jennifer MacDiarmid, said they were seeing high levels of high-affinity neutralising antibodies against all variants, including the now-common Omicron BA2, and a robust T cell and memory response in trial participants.
“So, even if the spike protein mutates or changes, EnGeneIC’s antibodies still stick to it tightly and neutralise it,” said Dr. Brahmbhatt.
“Additionally, the novel vaccine has a shelf life of one year and can be stored and transported at room temperature, making them be supply chain efficient while serving developing and remote locations.”
News & Trends - MedTech & Diagnostics
Roche Diagnostics MD bids farewell after two-decades, leading the organisation to new heights of success
Diagnostics & MedTech News: The Managing Director of Roche Diagnostics Australia, Allison Rossiter, has announced her resignation, effective September 2024. […]
MoreNews & Trends - Pharmaceuticals
Is Australia ready to play a leading role in precision nuclear medicines?
Pharma News: A newly released discussion paper unveils Australia’s preparedness to take the helm in the rise of the global […]
MoreNews & Trends - MedTech & Diagnostics
Minimally invasive procedure a first in epilepsy treatment
MedTech & Diagnostics News: An Australian-first procedure utilising MRI-guided, minimally invasive surgery has been introduced for the treatment of epilepsy […]
MoreNews & Trends - Pharmaceuticals
Stakeholders unite in international call to tackle breast cancer gaps and inequities
Pharma News: Breast Cancer Network Australia (BCNA) has united in an international call to raise breast cancer care standards and […]
More